Treatment outcome
infection
PAD, INFECTION, DISEASE PROGRESSION
A total of 26 patients received Rd as a continuous treatment after a median of 6 (range 4–9) cycles of bortezomib-containing triplet induction therapy (18 cases of VCD, 6 cases of VTD, 2 cases of PAD). In the Vd group, 32 patients received a median of 8 (range 4–10) cycles of bortezomib-containing triplet induction therapy (20 cases of VCD, 12 cases of VTD, 0 cases of PAD). At the data cutoff, 53.8% (14/26) of patients remained on Rd continuous treatment, the median cycle was 19 (range 4–36), 31.3% (10/32) of patients remained on Vd continuous treatment, and the median cycle was 11 (range 4–22). In the Rd group, the reason for the remaining 46.2% of patients who discontinued treatment was disease progression. No one experienced AE discontinuation. In the Vd group, 37.5% of patients discontinued treatment for disease progression, and 6.25% discontinued treatment for severe infection.The details of the response and comparison of efficacy between the Rd and Vd groups are shown in Table In the Rd group, the median follow-up was 32.8 months (5.2–71.4 months), and the OS and PFS of the entire cohort are shown in Fig. Kaplan–Meier survival curves. 